GlucoModicum needle-free MHD technology for non-invasive glucose monitoring achieves promising precision levels
More exciting news has surfaced in regard to a fully non-invasive, and painless, glucose monitor that could be safely used by millions of diabetics around the world. In this instance, the details come from GlucoModicum, which is a spin-off company from the highly regarded University of Helsinki in Finland. GlucoModicum has been working on measurement technology (MHD), a physical biosensor (“Talisman”), and a wearable continuous glucose monitor (“Flint”).
Apparently, data published by Biosensors and Bioelectronics came to the conclusion that the results “point to a possibility to combine magnetohydrodynamic extraction and glucose determination in a wearable device for non-invasive glucose monitoring”.
The report continues in its pragmatic but still optimistic tone:
Further development of the field of magnetohydrodynamic extraction of interstitial fluid through human skin together with an integrated biosensor will result in a new class of a needle- and microneedle-free medical device for glucose monitoring in people requiring diabetes management.
In addition, GlucoModicum’s MHD technology was found to be precise and accurate in its glucose molecule readings. Similar to other companies working on non-invasive glucose monitors, focus is placed on the interstitial fluid that flows between cells and blood vessels. As the firm points out, similar technology has been previously used with devices such as micropumps.
GlucoModicum wants to provide a whole package for people with diabetes, which includes the so-called Talisman sensor that operates with the requisite MHD technology to capture the data for accurate glucose measurement. On the firm's website, there is also a peek at the Flint CGM, which looks like a typical smartwatch. The plan is to make the device both compact and affordable, although there are no specific details for cost and launch date at the moment.
Clinical trials with the device have been positive, with one participant commenting that it “tracked my glucose levels on par with multiple blood samples done via finger pricking”. GlucoModicum states that it wants to make all the different components connected so that glucose level data can be continuously observed and checked via the cloud. Considering the expertise of the team behind this work and the involvement of one of the highest-rated universities in Europe, this non-invasive glucose monitor has to be one of the more promising solutions offered so far.
Source(s)
GlucoModicum (1/2/3) & ScienceDirect (PDF file)